The CSU indication is the seventh disease driven in part by underlying type 2 inflammation in which Dupixent has received approval.

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and ...

The FDA has approved Dupixent for chronic spontaneous urticaria in patients 12 and older unresponsive to antihistamines, ...

Chris Brookes-Smith could have died from eating peanuts - but taking part in a clinical trial has changed his life.

ADULTS can beat peanut allergies by eating tiny amounts with medical help and building up a tolerance, an NHS study suggests.

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with ...

Sanofi SNY and partner Regeneron REGN announced that the FDA approved Dupixent (dupilumab) for the treatment of chronic ...

The FDA approved dupilumab (Dupixent) for chronic spontaneous urticaria (CSU) in patients 12 years and older, the first new ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...

The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years ... spontaneous urticaria experience sudden, unpredictable hives ...

3 "The EC approval of RINVOQ in GCA provides patients and physicians with a new treatment option and the first oral advanced therapy for adults living with GCA – a particularly vulnerable ...

RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved in the European Union (EU) to treat adult patients with giant cell arteritis (GCA) The approval is supported by data from ...